ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$2.84
0.04 (1.61%)
▲
5d:
+3.47%
30d:
-0.18%
90d:
-18.53%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ACB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ACB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $2.83, which is considered slightly high relative to its 30-day fair value range of $2.65 to $2.81. From a valuation perspective, the stock is trading at a discount (Forward PE: -465.0) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a strong downtrend. The price is approaching resistance at $2.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.23 (+123.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACB is in a strong downtrend. The price is approaching resistance at $2.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.23 (+123.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.65 -
$2.81
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 123.2% below Wall St target ($6.23)
Trading Range Analysis
30-Day Trading Range
$2.65 -
$2.81
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.59
Resistance Level
$2.86
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-465.00
Wall Street Target
$6.23
(+123.2%)
Revenue Growth (YoY)
5.1%
Earnings Growth (YoY)
-94.7%
Profit Margin
-42.4%
PE vs Historical
-465.0 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: August 03, 2026 2:26 PM ET
Data refreshes hourly during market hours. Next update: 3:26 PM
Data refreshes hourly during market hours. Next update: 3:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
